Zoetis has today announced the launch of a new vaccine in the EU that protects against two of the main pathogens in the global pig industry.
CircoMax Myco is, according to Zoetis, the first, and only, vaccine that includes two porcine circovirus type 2 (PCV2) genotypes (a & b), providing broader coverage against PCV2 and longest-lasting combined protection against PCV2 and Mycoplasma hyopneumoniae (M Hyo).
It is designed to stimulate both cell-mediated and antibody-based immunity, providing a broad immune response that mimics a natural infection and has demonstrated robust performance in field conditions, delivering improvements in average daily gain (ADG) and final weights versus negative controls, helping producers get more kilograms of pork to market, Zoetis said.
CircoMax Myco comes in an easy to administer, ready to use single-dose combination with a duration of immunity (DOI) of 23 weeks against both PCV2 and M. Hyo. It is made with the MetaStim adjuvant and has a demonstrated safety profile, as described in the summary of product’s characteristics (SPC).
“The swine industry needs to adapt to evolving challenges and our research has consistently demonstrated that with its unique technology CircoMax Myco offers robust protection against PCV2 and M. hyopneumoniae,” said Alvaro Aldaz, director, global commercial development, swine, Zoetis.
“It also shows that this new product offers the best chance at protection against continuously evolving PCV2 genotypes – providing a broader umbrella for pig health and productivity. Analysis of new European PCV2 strains isolated in multiple countries confirm that CircoMax Myco offers broader coverage than competitor vaccines based on PCV2a only.”
Monica Balasch, director, global biologicals, Zoetis, added: “We believe that we need to be able to adapt to, and stay one step ahead of, evolving PCV2 genotypes. Our new vaccine, CircoMax Myco, offers high levels of efficacy, convenience and proven safety. This piglet vaccine, similar to other Zoetis products such as Suvaxyn PRRS MLV, will offer a robust long-lasting protection for healthy piglets against advancing threats.”
Porcine circovirus type 2 (PCV2) is the pathogen associated to porcine circovirus diseases (PCVD), which has brought significant economic losses to the pig industry.
PCV2 is the causal agent of Porcine Circovirus Systemic Disease (PCV-SD), previously called post-weaning multisystemic wasting syndrome (PMWS) and may result in secondary infections, particularly respiratory and reproductive diseases, diarrhoea, porcine dermatitis and nephropathy syndrome (PDNS) in infected pigs.
Mycoplasma hyopneumoniae causes economically very costly respiratory disease and is a core pathogen in the porcine respiratory disease complex (PRDC) that involves viruses, and enzootic pneumonia (EP) when associated to secondary bacteria.